fluconazole has been researched along with AIDS Seroconversion in 56 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disseminated cryptococcosis developed in an HIV antibody positive patient who was taking fluconazole for oral candidiasis." | 7.68 | Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole. ( Bell, D; Coker, RJ; Murphy, SM; Peters, BS, 1992) |
| "A systematic review of randomized clinical trials published between 1966 and April 2000 was undertaken to determine the strength of evidence for the effectiveness of antifungal drugs (nystatin, clotrimazole, amphotericin B, fluconazole, ketoconazole, and itraconazole) to prevent and treat oral candidiasis in human immunodeficiency virus-positive patients." | 4.81 | A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. ( Bonito, AJ; Patton, LL; Shugars, DA, 2001) |
| " We report here the evolution of a patient with disseminated cryptococcosis whose treatment failed after ten weeks of induction therapy with amphotericin B." | 3.73 | [Disseminated cryptococcosis as inaugural manifestation of AIDS]. ( Baur, AS; Bellini, C; Cavassini, M; Fournier, Y; Waeber, G, 2005) |
| "Disseminated cryptococcosis developed in an HIV antibody positive patient who was taking fluconazole for oral candidiasis." | 3.68 | Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole. ( Bell, D; Coker, RJ; Murphy, SM; Peters, BS, 1992) |
| "Fluconazole was effective against cryptococcal disease both before (aHR=11·0 [1·4-85·3]) and after start of antiretroviral therapy (no cases in fluconazole vs seven cases on placebo)." | 2.76 | Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. ( Coutinho, A; Grosskurth, H; Kamali, A; Lalloo, DG; Levin, J; Mugisha, NK; Namusoke, D; Parkes-Ratanshi, R; Wakeham, K; Whitworth, J, 2011) |
| "To evaluate a potential pharmacokinetic interaction of coadministration of fluconazole, and indinavir, a human immunodeficiency virus (HIV) protease inhibitor, 13 patients were enrolled in a multiple-dose, three-period, placebo-controlled, crossover study." | 2.69 | Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. ( Carides, A; Clumeck, N; De Smet, M; De Wit, S; Debier, M; Deutsch, P; Matthews, C; McCrea, J; Stone, J, 1998) |
| " There were no significant differences in other pharmacokinetic parameters, such as ddI peak concentrations in serum (971 +/- 509 and 942 +/- 442 ng/ml) or half-lives (80 +/- 32 and 85 +/- 21 min." | 2.68 | Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus. ( Bruzzese, VL; Gillum, JG; Israel, DS; Johnson, GL; Kaplowitz, LG; Polk, RE, 1995) |
| "16) in delavirdine pharmacokinetic parameters between treatment groups on day 15 or day 30." | 2.68 | Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. ( Anderson, RD; Borin, MT; Carel, BJ; Cox, SR; Freimuth, WW; Herman, BD, 1997) |
| "Cutaneous cryptococcosis is a systemic fungal disease; it is commonly observed in immunocompromised patients." | 2.39 | [Cryptococcal whitlow in a HIV positive patient]. ( Cren, P; Dompmartin, A; Duhamel, C; Galateau, F; Le Maitre, M; Leroy, D; Moreau, A; Six, M; Verneuil, L, 1995) |
| "Cryptococcosis is rare among children, only occurring in about 1% of children with HIV." | 1.38 | Disseminated cryptococcosis in an HIV-positive boy. ( Friedman, D; Kongthavonsakul, K; Oberdorfer, P, 2012) |
| "Two HIV-infected patients had recurrent cryptococcal meningitis (CM) despite treatment with fluconazole and immune reconstitution with combination antiretroviral therapy (CART)." | 1.35 | Recurrence of cryptococcal meningitis in HIV-infected patients following immune reconstitution. ( Corbett, EL; Ferrand, RA; Mangeya, N; Miller, RF; Seddon, J, 2009) |
| "Pulmonary sporotrichosis is rare and responds poorly to treatment." | 1.33 | Pulmonary Sporothrix schenckii infection in a HIV positive child. ( Behets, F; Callens, SF; Colebunders, R; Kitetele, F; Lelo, P; Lukun, P; Van Rie, A, 2006) |
| "Fungal peritonitis is rarely encountered." | 1.31 | Trichosporon beigelii peritonitis in a HIV-positive patient on continuous ambulatory peritoneal dialysis. ( Agarwal, SK; Anuradha, S; Bajaj, J; Chatterjee, A; Kaur, R; Singh, NP, 2000) |
| "Fluconazole was well tolerated by all patients and there were no significant changes in haematological or hepatic parameters that could be attributed to the drug." | 1.27 | Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. ( Drouhet, E; Dupont, B, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.57) | 18.7374 |
| 1990's | 26 (46.43) | 18.2507 |
| 2000's | 15 (26.79) | 29.6817 |
| 2010's | 13 (23.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beyene, T | 1 |
| Zewde, AG | 1 |
| Balcha, A | 1 |
| Hirpo, B | 1 |
| Yitbarik, T | 1 |
| Gebissa, T | 1 |
| Rajasingham, R | 1 |
| Boulware, DR | 1 |
| Molloy, SF | 1 |
| Kanyama, C | 1 |
| Heyderman, RS | 1 |
| Loyse, A | 1 |
| Kouanfack, C | 1 |
| Chanda, D | 1 |
| Mfinanga, S | 1 |
| Temfack, E | 1 |
| Lakhi, S | 1 |
| Lesikari, S | 1 |
| Chan, AK | 1 |
| Stone, N | 1 |
| Kalata, N | 1 |
| Karunaharan, N | 1 |
| Gaskell, K | 1 |
| Peirse, M | 1 |
| Ellis, J | 1 |
| Chawinga, C | 1 |
| Lontsi, S | 1 |
| Ndong, JG | 1 |
| Bright, P | 1 |
| Lupiya, D | 1 |
| Chen, T | 1 |
| Bradley, J | 1 |
| Adams, J | 1 |
| van der Horst, C | 1 |
| van Oosterhout, JJ | 1 |
| Sini, V | 1 |
| Mapoure, YN | 1 |
| Mwaba, P | 1 |
| Bicanic, T | 1 |
| Lalloo, DG | 2 |
| Wang, D | 1 |
| Hosseinipour, MC | 1 |
| Lortholary, O | 2 |
| Jaffar, S | 1 |
| Harrison, TS | 2 |
| Awotiwon, AA | 1 |
| Johnson, S | 1 |
| Rutherford, GW | 1 |
| Meintjes, G | 1 |
| Eshun-Wilson, I | 1 |
| Tambe, S | 1 |
| Zambare, U | 1 |
| Nayak, C | 1 |
| Kitonsa, J | 1 |
| Mayanja, Y | 1 |
| Aling, E | 1 |
| Kiwanuka, J | 1 |
| Namutundu, J | 1 |
| Anywaine, Z | 1 |
| Ggayi, AB | 1 |
| Kibengo, F | 1 |
| Kiwanuka, N | 1 |
| Kaleebu, P | 1 |
| Das, PP | 1 |
| Saikia, L | 1 |
| Nath, R | 1 |
| Phukan, SK | 1 |
| Monpoux, F | 1 |
| Pitelet, G | 1 |
| Richelme, C | 1 |
| Boutté, P | 1 |
| Seilmaier, M | 1 |
| Hecht, A | 1 |
| Guggemos, W | 1 |
| Rüdisser, K | 1 |
| Seddon, J | 1 |
| Mangeya, N | 1 |
| Miller, RF | 2 |
| Corbett, EL | 1 |
| Ferrand, RA | 1 |
| Arechavala, AI | 1 |
| Ochiuzzi, ME | 1 |
| Borgnia, MD | 1 |
| Santiso, GM | 1 |
| Rybniker, J | 1 |
| Goede, V | 1 |
| Mertens, J | 1 |
| Ortmann, M | 1 |
| Kulas, W | 1 |
| Kochanek, M | 1 |
| Benzing, T | 1 |
| Arribas, JR | 1 |
| Fätkenheuer, G | 1 |
| Kreft, B | 1 |
| Oehme, A | 1 |
| Lübbert, C | 1 |
| Marsch, WC | 1 |
| Kekulé, AS | 1 |
| Parkes-Ratanshi, R | 1 |
| Wakeham, K | 1 |
| Levin, J | 1 |
| Namusoke, D | 1 |
| Whitworth, J | 1 |
| Coutinho, A | 1 |
| Mugisha, NK | 1 |
| Grosskurth, H | 1 |
| Kamali, A | 1 |
| Klausner, JD | 1 |
| Govender, N | 1 |
| Oladoyinbo, S | 1 |
| Roy, M | 1 |
| Chiller, T | 1 |
| Friedman, D | 1 |
| Kongthavonsakul, K | 1 |
| Oberdorfer, P | 1 |
| Sornum, A | 1 |
| Pagani, JL | 1 |
| Chave, JP | 1 |
| Casjka, C | 1 |
| Glauser, MP | 1 |
| Bille, J | 1 |
| Lattif, AA | 1 |
| Banerjee, U | 1 |
| Prasad, R | 1 |
| Biswas, A | 1 |
| Wig, N | 1 |
| Sharma, N | 1 |
| Haque, A | 1 |
| Gupta, N | 1 |
| Baquer, NZ | 1 |
| Mukhopadhyay, G | 1 |
| Fournier, Y | 1 |
| Bellini, C | 1 |
| Baur, AS | 1 |
| Waeber, G | 1 |
| Cavassini, M | 1 |
| Callens, SF | 1 |
| Kitetele, F | 1 |
| Lukun, P | 1 |
| Lelo, P | 1 |
| Van Rie, A | 1 |
| Behets, F | 1 |
| Colebunders, R | 2 |
| de Souza, JA | 1 |
| Sivasangeetha, K | 1 |
| Harish, BN | 1 |
| Sujatha, S | 1 |
| Parija, SC | 1 |
| Dutta, TK | 1 |
| Viard, JP | 1 |
| Hennequin, C | 1 |
| Fortineau, N | 1 |
| Pertuiset, N | 1 |
| Rothschild, C | 1 |
| Zylberberg, H | 1 |
| Bruzzese, VL | 1 |
| Gillum, JG | 1 |
| Israel, DS | 1 |
| Johnson, GL | 1 |
| Kaplowitz, LG | 1 |
| Polk, RE | 1 |
| Lucas, SB | 1 |
| De Cock, KM | 1 |
| Hay, RJ | 1 |
| Imbert-Bernard, C | 1 |
| Valentin, A | 1 |
| Reynes, J | 2 |
| Mallié, M | 2 |
| Bastide, JM | 2 |
| Cameron, ML | 1 |
| Schell, WA | 1 |
| Bruch, S | 1 |
| Bartlett, JA | 1 |
| Waskin, HA | 1 |
| Perfect, JR | 1 |
| Essayag, SM | 1 |
| Baily, GG | 1 |
| Denning, DW | 1 |
| Burnie, JP | 1 |
| Verneuil, L | 1 |
| Dompmartin, A | 1 |
| Duhamel, C | 1 |
| Cren, P | 1 |
| Six, M | 1 |
| Le Maitre, M | 1 |
| Galateau, F | 1 |
| Moreau, A | 1 |
| Leroy, D | 1 |
| Cartledge, JD | 2 |
| Midgley, J | 2 |
| Gazzard, BG | 2 |
| Dannaoui, E | 1 |
| Colin, S | 1 |
| Pichot, J | 1 |
| Piens, MA | 1 |
| Laguna, F | 1 |
| Valencia, E | 1 |
| Polo, R | 1 |
| Moreno, V | 1 |
| González-Lahoz, JM | 1 |
| Schoofs, A | 1 |
| Odds, FC | 1 |
| Ieven, M | 1 |
| Wouters, L | 1 |
| Goossens, H | 1 |
| Borin, MT | 1 |
| Cox, SR | 1 |
| Herman, BD | 1 |
| Carel, BJ | 1 |
| Anderson, RD | 1 |
| Freimuth, WW | 1 |
| Tortorano, AM | 1 |
| Viviani, MA | 1 |
| Rigoni, AL | 1 |
| Cogliati, M | 1 |
| Roverselli, A | 1 |
| Pagano, A | 1 |
| De Wit, S | 1 |
| Debier, M | 1 |
| De Smet, M | 1 |
| McCrea, J | 1 |
| Stone, J | 1 |
| Carides, A | 1 |
| Matthews, C | 1 |
| Deutsch, P | 1 |
| Clumeck, N | 1 |
| Rogowska-Szadkowska, D | 1 |
| Wiercińska-Drapało, A | 1 |
| Borzuchowska, A | 1 |
| Prokopowicz, D | 1 |
| Hunter, KD | 1 |
| Gibson, J | 1 |
| Lockhart, P | 1 |
| Pithie, A | 1 |
| Bagg, J | 1 |
| Jabra-Rizk, MA | 2 |
| Baqui, AA | 2 |
| Kelley, JI | 2 |
| Falkler, WA | 2 |
| Merz, WG | 2 |
| Meiller, TF | 2 |
| Bellibas, SE | 1 |
| Pujol, C | 1 |
| Meeks, VI | 1 |
| Bernal, S | 1 |
| Gutiérrez, MJ | 1 |
| Serrano, MC | 1 |
| Chávez, M | 1 |
| Valverde, A | 1 |
| Quindós, G | 1 |
| Mazuelos, EM | 1 |
| Rimek, D | 1 |
| Zimmermann, T | 1 |
| Hartmann, M | 1 |
| Prariyachatigul, C | 1 |
| Kappe, R | 1 |
| Anuradha, S | 1 |
| Chatterjee, A | 1 |
| Bajaj, J | 1 |
| Singh, NP | 1 |
| Agarwal, SK | 1 |
| Kaur, R | 1 |
| Patton, LL | 1 |
| Bonito, AJ | 1 |
| Shugars, DA | 1 |
| Lasker, BA | 1 |
| Elie, CM | 1 |
| Lott, TJ | 1 |
| Espinel-Ingroff, A | 1 |
| Gallagher, L | 1 |
| Kuykendall, RJ | 1 |
| Kellum, ME | 1 |
| Pruitt, WR | 1 |
| Warnock, DW | 1 |
| Rimland, D | 1 |
| McNeil, MM | 1 |
| Reiss, E | 1 |
| Martins, RS | 1 |
| Péreira, ES | 1 |
| Lima, SM | 1 |
| Senna, MI | 1 |
| Mesquita, RA | 1 |
| Santos, VR | 1 |
| Mínguez Castellanos, A | 1 |
| Ortega Moreno, A | 1 |
| Vilches Carrillo, RM | 1 |
| Foronda Bengoa, J | 1 |
| Coker, RJ | 1 |
| Bell, D | 1 |
| Peters, BS | 1 |
| Murphy, SM | 1 |
| Gussenhoven, MJ | 1 |
| Haak, A | 1 |
| Peereboom-Wynia, JD | 1 |
| van 't Wout, JW | 1 |
| Franklin, IM | 1 |
| Elias, E | 1 |
| Hirsch, C | 1 |
| Holmes, J | 1 |
| Clements, D | 1 |
| Dupont, B | 1 |
| Drouhet, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comprehensive Diagnosis and Treatment Strategy for Opportunistic Fungal Infections in AIDS Patients[NCT05153005] | 600 participants (Anticipated) | Observational | 2021-04-01 | Recruiting | |||
| A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis[NCT00885703] | Phase 1/Phase 2 | 168 participants (Actual) | Interventional | 2010-04-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change in quantitative CSF (cerebrospinal fluid) cultures.~Note: No further CSF specimens are drawn following a negative culture. Thus, only week 2 CSF cultures are considered in this analysis." (NCT00885703)
Timeframe: Entry and Week 2
| Intervention | Log10 CFU/mL (Median) |
|---|---|
| Fluconazole 1200mg | -1.51 |
| Fluconazole 1600mg | -2.51 |
| Fluconazole 2000mg | -1.78 |
| Ampho B | -2.81 |
Kaplan Meier Proportion of participants who died over study with 90% Confidence Intervals. (NCT00885703)
Timeframe: Measured from study entry through Week 24
| Intervention | proportion of participants (Number) |
|---|---|
| Fluconazole 1200mg | 0.41 |
| Fluconazole 1600mg | 0.30 |
| Fluconazole 2000mg | 0.36 |
| Ampho B | 0.24 |
Duration of first hospitalization in days starting at entry in safety population. (NCT00885703)
Timeframe: Measured from study entry through Week 10
| Intervention | Days (Median) |
|---|---|
| Fluconazole 1200mg | 15 |
| Fluconazole 1600mg | 17.5 |
| Fluconazole 2000mg | 18 |
| Ampho B | 18.5 |
"Discontinuation of study-provided high dose fluconazole at or by week 10 Discontinuation of study-provided ampho B at or by week 2~Discontinuation includes discontinuing for any reason, including progression of symptoms, death, etc." (NCT00885703)
Timeframe: Measured from study entry through Week10
| Intervention | Participants (Count of Participants) |
|---|---|
| Stage 1, Fluconazole 1200mg | 14 |
| Stage 1, Fluconazole 1600mg | 11 |
| Stage 1, Fluconazole 2000mg | 11 |
| Stage 1, Ampho B | 6 |
| Stage 2, Fluconazole 1600mg | 12 |
| Stage 2, Fluconazole 2000mg | 13 |
| Stage 2, Ampho B | 6 |
Number of participants who were diagnosed with CNS immune reconstitution inflammatory syndrome (IRIS) (NCT00885703)
Timeframe: Measured from study entry through Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Fluconazole 1200mg | 1 |
| Fluconazole 1600mg | 0 |
| Fluconazole 2000mg | 0 |
| Ampho B | 1 |
"Progression of symptoms is defined as:~Died (including early deaths)~Discontinued Fluconazole and started ampho B~Had a positive cryptococcal culture at week 10~Microbiological Failure (i.e., relapse of CM)~Complication of CM (e.g., obstructive hydrocephalus or vascular complications such as venous or arterial thrombosis)~CM IRIS causing increased inflammation after ART exposure~New CNS Ol (e.g., toxoplasmosis, PML, CNS lymphoma)~Possibly related to CM but mechanism indeterminate~Other defined complication unrelated to CM" (NCT00885703)
Timeframe: Measured from study entry through Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Fluconazole 1200mg | 14 |
| Fluconazole 1600mg | 21 |
| Fluconazole 2000mg | 24 |
| Ampho B | 19 |
"Occurrence of grade 3 (severe) and 4 (life-threatening) sign and symptoms events (as defined by FSTRF Appendix 29)~Occurrence of grade 3 (severe) and 4 (life-threatening) laboratory events (as defined by FSTRF Appendix 76)~See DAIDS AE Grading table V1.0" (NCT00885703)
Timeframe: Measured from study entry through Week 24
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Sign/Symptom Events | Laboratory Events | |
| Ampho B | 24 | 30 |
| Fluconazole 1200mg | 16 | 12 |
| Fluconazole 1600mg | 23 | 27 |
| Fluconazole 2000mg | 32 | 26 |
"Functional assessment of work status and ability. Consists of 2 measures: 1) Does participants have full time work status 2) Does participant have functional ability to work.~The measure from 6 week before enrollment will be referred to as 'baseline'." (NCT00885703)
Timeframe: Measured 6 weeks before enrollment, at study entry, at Week 10, and at Week 24
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline Had full time work status | Entry Had full time work status | Week 10 Had full time work status | Week 24 Had full time work status | Baseline Had functional ability to work | Entry Had functional ability to work | Week 10 Had functional ability to work | Week 24 Had functional ability to work | |
| Ampho B | 42 | 9 | 13 | 22 | 38 | 7 | 15 | 24 |
| Fluconazole 1200mg | 18 | 3 | 3 | 7 | 16 | 1 | 4 | 7 |
| Fluconazole 1600mg | 41 | 9 | 16 | 18 | 41 | 8 | 18 | 19 |
| Fluconazole 2000mg | 36 | 8 | 9 | 17 | 32 | 3 | 9 | 16 |
Count of participants who were CM negative (had no cryptococcal growth), CM negative after switching treatment (switched from Fluconazole to Ampho B or vice versa and later became CM negative), CM positive, Died, Lost to follow-up. Note: CM positive means continued to have cryptococcal growth. (NCT00885703)
Timeframe: At entry, Week 2, and Week 10
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 072337496 | Week 072337498 | Week 072337499 | Week 072337497 | Week 272337496 | Week 272337497 | Week 272337498 | Week 272337499 | Week 1072337496 | Week 1072337497 | Week 1072337498 | Week 1072337499 | |||||||||||||||||||||||||||||||||||||||||||||||||
| CM Negative after switching treatment | Died | Lost to Follow-up | CM Positive | CM Negative | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Results from Glasgow Coma Score, which provides assessment of impairment of conscious level in response to defined stimuli. Min score of 0 and max score of 15 (no mental impairment). (NCT00885703)
Timeframe: Measured at study entry, Week 2, and Week 10
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 072337496 | Week 072337497 | Week 072337498 | Week 072337499 | Week 272337496 | Week 272337497 | Week 272337498 | Week 272337499 | Week 1072337497 | Week 1072337498 | Week 1072337496 | Week 1072337499 | |||||||||||||
| Score = 15 | Score < 15 | |||||||||||||||||||||||
| Fluconazole 1200mg | 5 | |||||||||||||||||||||||
| Fluconazole 1600mg | 5 | |||||||||||||||||||||||
| Fluconazole 2000mg | 5 | |||||||||||||||||||||||
| Ampho B | 1 | |||||||||||||||||||||||
| Fluconazole 1200mg | 17 | |||||||||||||||||||||||
| Fluconazole 1600mg | 45 | |||||||||||||||||||||||
| Fluconazole 2000mg | 42 | |||||||||||||||||||||||
| Ampho B | 47 | |||||||||||||||||||||||
| Fluconazole 1200mg | 2 | |||||||||||||||||||||||
| Fluconazole 1600mg | 4 | |||||||||||||||||||||||
| Fluconazole 2000mg | 4 | |||||||||||||||||||||||
| Ampho B | 5 | |||||||||||||||||||||||
| Fluconazole 1200mg | 15 | |||||||||||||||||||||||
| Fluconazole 1600mg | 38 | |||||||||||||||||||||||
| Fluconazole 2000mg | 36 | |||||||||||||||||||||||
| Ampho B | 38 | |||||||||||||||||||||||
| Fluconazole 1200mg | 1 | |||||||||||||||||||||||
| Fluconazole 1600mg | 1 | |||||||||||||||||||||||
| Fluconazole 2000mg | 1 | |||||||||||||||||||||||
| Ampho B | 0 | |||||||||||||||||||||||
| Fluconazole 1200mg | 11 | |||||||||||||||||||||||
| Fluconazole 1600mg | 33 | |||||||||||||||||||||||
| Fluconazole 2000mg | 26 | |||||||||||||||||||||||
| Ampho B | 34 | |||||||||||||||||||||||
4 reviews available for fluconazole and AIDS Seroconversion
| Article | Year |
|---|---|
Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Cause of Death; CD4 Lympho | 2018 |
Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Drug Therapy, Com | 2010 |
[Cryptococcal whitlow in a HIV positive patient].
Topics: Aged; Cryptococcosis; Cryptococcus neoformans; Dermatomycoses; Fingers; Fluconazole; Hand Dermatoses | 1995 |
A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candidiasis; Candidiasis, | 2001 |
7 trials available for fluconazole and AIDS Seroconversion
| Article | Year |
|---|---|
Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa.
Topics: Administration, Oral; Adult; Africa; AIDS-Related Opportunistic Infections; Amphotericin B; Antifung | 2018 |
Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cohort Studies; Dru | 2019 |
Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antifungal Agents; CD4 Lymphoc | 2011 |
Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Candidiasis, Oral; Double-Blind Method; Drug Resistanc | 2002 |
Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus.
Topics: Adult; Didanosine; Drug Interactions; Female; Fluconazole; Half-Life; HIV Seropositivity; Humans; Ma | 1995 |
Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cy | 1997 |
Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Cross-Over Studies; Double-Blind Method; Dru | 1998 |
45 other studies available for fluconazole and AIDS Seroconversion
| Article | Year |
|---|---|
Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Cryptococcus; Eth | 2017 |
Nodulo-ulcerative and erythrodermic secondary syphilis in human immunodeficiency virus-infected individuals.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Chancre; | 2019 |
Species distribution & antifungal susceptibility pattern of oropharyngeal Candida isolates from human immunodeficiency virus infected individuals.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Candida; Candidiasis; Child; Child, | 2016 |
[A case of acquired encephalopathy in a child. A cause that we thought had disappeared].
Topics: AIDS Dementia Complex; Anti-HIV Agents; Anti-Infective Agents; Drug Therapy, Combination; Female; Fl | 2008 |
[Cryptococcal meningoencephalitis related to HIV infection with resistance to fluconazole, relapse, and IRIS].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Cryptococcus neofo | 2009 |
Recurrence of cryptococcal meningitis in HIV-infected patients following immune reconstitution.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifunga | 2009 |
Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Female; Fluconazo | 2009 |
[37-year old patient with fever, diarrhea and lymphadenopathy].
Topics: Adult; AIDS Serodiagnosis; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antifungal | 2010 |
Prevention of AIDS-associated cryptococcosis in resource-poor areas.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Cryptococcosis; Female; Fluconazole; HIV Seropositivity; | 2011 |
Preventing AIDS deaths: cryptococcal antigen screening and treatment.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Cryptococcosis; Female; Fluconazole; HIV Seropositivity; | 2012 |
Disseminated cryptococcosis in an HIV-positive boy.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Child; Cr | 2012 |
A mistaken diagnosis of Molluscum contagiosum in a HIV-positive patient in rural South Africa.
Topics: Adult; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Diagnostic Errors; Facial Dermato | 2012 |
Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients.
Topics: AIDS-Related Opportunistic Infections; Candida; Candidiasis, Oral; CD4 Lymphocyte Count; DNA Fingerp | 2004 |
[Disseminated cryptococcosis as inaugural manifestation of AIDS].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Biopsy; Cryptococco | 2005 |
Pulmonary Sporothrix schenckii infection in a HIV positive child.
Topics: Antifungal Agents; Child; Democratic Republic of the Congo; Fluconazole; HIV Seropositivity; Humans; | 2006 |
Molluscum or a mimic?
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiretroviral Ther | 2006 |
Cryptococcal meningoencephalitis diagnosed by blood culture.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococc | 2007 |
Fulminant cryptococcal infections in HIV-infected patients on oral fluconazole.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Candidiasis, Oral; Cryptococcosi | 1995 |
Disseminated cryptococcal infection despite treatment for cryptococcal meningitis.
Topics: Adult; Amphotericin B; Cryptococcosis; Fatal Outcome; Fluconazole; HIV Seropositivity; Humans; Male; | 1995 |
Relationship between fluconazole sensitivity of Candida albicans isolates from HIV positive patients and serotype, adherence and CD4+ lymphocyte count.
Topics: AIDS-Related Opportunistic Infections; Candida albicans; Candidiasis, Oral; CD4 Lymphocyte Count; Co | 1994 |
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.
Topics: Adult; Candida albicans; Candidiasis, Oral; Drug Resistance, Microbial; Female; Fluconazole; HIV Ser | 1993 |
Karyotyping of fluconazole-resistant yeasts with phenotype reported as Candida krusei or Candida inconspicua.
Topics: Antifungal Agents; Candida; Candidiasis; Chromosomes, Fungal; DNA, Fungal; Drug Resistance, Microbia | 1996 |
Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidosis.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis, Oral; Drug Resistanc | 1996 |
Evaluation of the E test for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis, Oral; CD4 Lymphocyte Count; Flucon | 1997 |
[Oral amphotericin B inefficacy in the treatment of fluconazole++ resistant oropharyngeal candidiasis in HIV-positive patients].
Topics: Adult; Amphotericin B; Antifungal Agents; Candidiasis, Oral; Drug Resistance, Microbial; Fluconazole | 1996 |
Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes.
Topics: Antifungal Agents; Candida; Cell Division; Culture Media; DNA Fingerprinting; DNA, Fungal; Fluconazo | 1997 |
Prevalence of serotype D in Cryptococcus neoformans isolates from HIV positive and HIV negative patients in Italy.
Topics: Adolescent; Adult; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Europe; Female; Fluco | 1997 |
[Candida humicola infection of the central nervous system in an HIV-infected patient: a case report].
Topics: Adult; Antifungal Agents; Brain; Candidiasis, Oral; Fatal Outcome; Fluconazole; HIV Seropositivity; | 1997 |
Fluconazole-resistant Candida species in the oral flora of fluconazole-exposed HIV-positive patients.
Topics: Adult; Agar; Antifungal Agents; Candida; Candida albicans; Candidiasis, Oral; CD4 Lymphocyte Count; | 1998 |
Transmission of fluconazole-resistant Candida strains between HIV-positive patients and their sexual partners.
Topics: Antifungal Agents; Candida; Candidiasis, Oral; Drug Resistance, Microbial; Female; Fluconazole; HIV | 1998 |
Identification of Candida dubliniensis in a prospective study of patients in the United States.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis, Oral; Culture | 1999 |
Indinavir-fluconazole interaction.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Drug Interactions; Flucon | 1999 |
[Genotype, serotype and sensitivity to fluconazole of Candida albicans strains isolated from HIV-positive patients].
Topics: Antifungal Agents; Candida albicans; Fluconazole; Genotype; HIV Seropositivity; Humans; Microbial Se | 1999 |
Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States.
Topics: Antifungal Agents; Candida; Candidiasis, Oral; DMF Index; DNA, Fungal; Female; Fluconazole; HIV Sero | 1999 |
[Susceptibility to fluconazole and itraconazole in isolates of Candida spp. from HIV-positive and HIV-negative patients].
Topics: Antifungal Agents; Candida; Fluconazole; HIV Seronegativity; HIV Seropositivity; Humans; Itraconazol | 2000 |
Disseminated Penicillium marneffei infection in an HIV-positive female from Thailand in Germany.
Topics: Adult; Amphotericin B; Anti-HIV Agents; Antifungal Agents; CD4 Lymphocyte Count; Cross Reactions; Dr | 1999 |
Trichosporon beigelii peritonitis in a HIV-positive patient on continuous ambulatory peritoneal dialysis.
Topics: Adult; AIDS-Related Opportunistic Infections; Fluconazole; Follow-Up Studies; HIV Seropositivity; Hu | 2000 |
Molecular epidemiology of Candida albicans strains isolated from the oropharynx of HIV-positive patients at successive clinic visits.
Topics: Adult; AIDS-Related Opportunistic Infections; Ambulatory Care; Antifungal Agents; Candida albicans; | 2001 |
Effect of commercial ethanol propolis extract on the in vitro growth of Candida albicans collected from HIV-seropositive and HIV-seronegative Brazilian patients with oral candidiasis.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Brazil; Candida alb | 2002 |
[Cryptococcal meningitis in an immunocompetent patient: efficacy of fluconazole].
Topics: Adult; AIDS-Related Opportunistic Infections; Fluconazole; HIV Seropositivity; Humans; Immunocomprom | 1992 |
Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole.
Topics: Adult; Candidiasis, Oral; Cryptococcosis; Fluconazole; HIV Seropositivity; Humans; Lung Diseases, Fu | 1992 |
Stevens-Johnson syndrome after fluconazole.
Topics: Adult; Candidiasis, Oral; Fluconazole; HIV Seropositivity; Homosexuality; Humans; Male; Stevens-John | 1991 |
Fluconazole-induced jaundice.
Topics: Adult; Candidiasis; Candidiasis, Chronic Mucocutaneous; Fluconazole; HIV Seropositivity; Humans; Jau | 1990 |
Jaundice in HIV positive haemophiliac.
Topics: Adult; Antifungal Agents; Candidiasis, Oral; Fluconazole; Hemophilia A; HIV Seropositivity; Humans; | 1989 |
Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients.
Topics: Adult; Aged; Candida albicans; Candidiasis; Candidiasis, Oral; Female; Fluconazole; HIV Seropositivi | 1988 |